Literature DB >> 33717044

New Insights Into the Antibacterial Mechanism of Cryptotanshinone, a Representative Diterpenoid Quinone From Salvia miltiorrhiza Bunge.

Bo-Chen Chen1, Zhi-Shan Ding2, Jian-Sheng Dai1, Ni-Pi Chen1, Xing-Wen Gong3, Lie-Feng Ma4, Chao-Dong Qian1.   

Abstract

The rapid rise of antibiotic resistance causes an urgent need for new antimicrobial agents with unique and different mechanisms of action. The respiratory chain is one such target involved in the redox balance and energy metabolism. As a natural quinone compound isolated from the root of Salvia miltiorrhiza Bunge, cryptotanshinone (CT) has been previously demonstrated against a wide range of Gram-positive bacteria including multidrug-resistant pathogens. Although superoxide radicals induced by CT are proposed to play an important role in the antibacterial effect of this agent, its mechanism of action is still unclear. In this study, we have shown that CT is a bacteriostatic agent rather than a bactericidal agent. Metabolome analysis suggested that CT might act as an antibacterial agent targeting the cell membrane. CT did not cause severe damage to the bacterial membrane but rapidly dissipated membrane potential, implying that this compound could be a respiratory chain inhibitor. Oxygen consumption analysis in staphylococcal membrane vesicles implied that CT acted as respiratory chain inhibitor probably by targeting type II NADH:quinone dehydrogenase (NDH-2). Molecular docking study suggested that the compound would competitively inhibit the binding of quinone to NDH-2. Consistent with the hypothesis, the antimicrobial activity of CT was blocked by menaquinone, and the combination of CT with thioridazine but not 2-n-heptyl-4-hydroxyquinoline-N-oxide exerted synergistic activity against Staphylococcus aureus. Additionally, combinations of CT with other inhibitors targeting different components of the bacterial respiratory chain exhibit potent synergistic activities against S. aureus, suggesting a promising role in combination therapies.
Copyright © 2021 Chen, Ding, Dai, Chen, Gong, Ma and Qian.

Entities:  

Keywords:  cryptotanshinone; menaquinone; metabolome analysis; respiratory chain inhibitor; type II NADH:quinone dehydrogenase

Year:  2021        PMID: 33717044      PMCID: PMC7950322          DOI: 10.3389/fmicb.2021.647289

Source DB:  PubMed          Journal:  Front Microbiol        ISSN: 1664-302X            Impact factor:   5.640


  41 in total

1.  A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.

Authors:  Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier
Journal:  Science       Date:  2004-12-09       Impact factor: 47.728

2.  Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane.

Authors:  Hiroshi Hamamoto; Makoto Urai; Kenichi Ishii; Jyunichiro Yasukawa; Atmika Paudel; Motoki Murai; Takuya Kaji; Takefumi Kuranaga; Kenji Hamase; Takashi Katsu; Jie Su; Tatsuo Adachi; Ryuji Uchida; Hiroshi Tomoda; Maki Yamada; Manabu Souma; Hiroki Kurihara; Masayuki Inoue; Kazuhisa Sekimizu
Journal:  Nat Chem Biol       Date:  2014-12-08       Impact factor: 15.040

Review 3.  Antimicrobial plant metabolites: structural diversity and mechanism of action.

Authors:  N S Radulović; P D Blagojević; Z Z Stojanović-Radić; N M Stojanović
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

4.  Inhibition of membrane potential-dependent amino acid transport by daptomycin.

Authors:  N E Allen; W E Alborn; J N Hobbs
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

5.  Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs.

Authors:  Edward A Weinstein; Takahiro Yano; Lin-Sheng Li; David Avarbock; Andrew Avarbock; Douglas Helm; Andrew A McColm; Ken Duncan; John T Lonsdale; Harvey Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-14       Impact factor: 11.205

6.  A cytochrome bb'-type quinol oxidase in Bacillus subtilis strain 168.

Authors:  N Azarkina; S Siletsky; V Borisov; C von Wachenfeldt; L Hederstedt; A A Konstantinov
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

Review 7.  Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections.

Authors:  Julian G Hurdle; Alex J O'Neill; Ian Chopra; Richard E Lee
Journal:  Nat Rev Microbiol       Date:  2011-01       Impact factor: 60.633

8.  Antibacterial activities of cryptotanshinone and dihydrotanshinone I from a medicinal herb, Salvia miltiorrhiza Bunge.

Authors:  D S Lee; S H Lee; J G Noh; S D Hong
Journal:  Biosci Biotechnol Biochem       Date:  1999-12       Impact factor: 2.043

9.  Phosphatidic acid plays a special role in stabilizing and folding of the tetrameric potassium channel KcsA.

Authors:  Mobeen Raja; Robin E J Spelbrink; Ben de Kruijff; J Antoinette Killian
Journal:  FEBS Lett       Date:  2007-11-26       Impact factor: 4.124

10.  Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generation.

Authors:  Adam Heikal; Yoshio Nakatani; Elyse Dunn; Marion R Weimar; Catherine L Day; Edward N Baker; J Shaun Lott; Leonid A Sazanov; Gregory M Cook
Journal:  Mol Microbiol       Date:  2014-01-21       Impact factor: 3.501

View more
  2 in total

1.  Cryptotanshinone ameliorates CUS-induced depressive-like behaviors in mice.

Authors:  Kaixin Wang; Qingling Zhai; Sanwang Wang; Qiongyu Li; Jing Liu; Fantao Meng; Wentao Wang; Jinjie Zhang; Dan Wang; Di Zhao; Cuilan Liu; Juanjuan Dai; Chen Li; Minghu Cui; Jinbo Chen
Journal:  Transl Neurosci       Date:  2021-11-30       Impact factor: 1.757

Review 2.  Antimicrobial Diterpenes: Recent Development From Natural Sources.

Authors:  Poushali Saha; Fahad Imtiaz Rahman; Fahad Hussain; S M Abdur Rahman; M Mukhlesur Rahman
Journal:  Front Pharmacol       Date:  2022-02-28       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.